Substance Use Disorders
4 articles on Substance Use Disorders, written by Shotlee and medically reviewed for clinical accuracy.
GLP-1s Reduce Substance Addiction Risk in US Veterans: BMJ Study
An observational study in the British Medical Journal reveals GLP-1 medications like semaglutide significantly lower substance use disorder (SUD) risk in US veterans with type 2 diabetes. Compared to SGLT2 inhibitors, GLP-1s reduced new addiction risks by up to 25% and improved outcomes like 50% fewer substance-related deaths. These findings challenge traditional views on addiction and metabolic health.
5 min read
Study: GLP-1 Drugs May Fight Addiction Across Major Substances
Patients on GLP-1 drugs like Ozempic report losing interest in cigarettes, alcohol, and more without effort. A physician-led study of over 600,000 VA patients reveals these medications cut addiction-related deaths by 50% and prevent new substance use disorders. This could transform treatment for alcohol, opioids, cocaine, cannabis, and nicotine.
5 min read
Ozempic May Lower Addiction Risk, New BMJ Study Shows
A groundbreaking BMJ study reveals GLP-1 drugs like Ozempic may reduce the risk of developing substance use disorders by 14% in diabetes patients. Among those with existing addictions, hospital admissions dropped 26%. While promising, these are associations from veteran health records—randomized trials are needed for proof.
5 min read
GLP-1s Curb Cravings Beyond Food: 600K Study Suggests
Patients on GLP-1 drugs report losing cravings not just for food, but for cigarettes, alcohol, and more—without effort. A new study of over 600,000 people confirms dramatic reductions in overdoses, deaths, and new addictions. Could semaglutide and tirzepatide redefine addiction care?
5 min read